Cite
HARVARD Citation
Strosberg, J. et al. (2021). 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet oncology. 22 (12), pp. 1752-1763. [Online].